Cellectis Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

About Cellectis Contact Number

Phone Number (Optional) Message * I would like to receive information from the Cellectis Group by email . Send it. Legal Notice- subscription and contact forms- Cellectis Legal notice Glossary Media library Contact Community guidelines. Subsidiary: Calyxt Inc.

Contact US: https://www.cellectis.com/en/contact

Who is Cellectis and what do they do?

Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer

When does Cellectis report for the fourth quarter?

March 4, 2021 – New York – Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), today announced its results for the fourth quarter of 2020, and full year ending December 31, 2020.

When did Cellartis get acquired by Cellectis?

The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools today. Cellartis was acquired by Cellectis on Sep 15, 2011.

Where is Cellectis manufacturing facility in Paris France?

In addition, Cellectis started building a 14,000 square foot manufacturing facility in Paris, France named SMART (Starting Material Realization for CAR-T products) to produce Cellectis’ critical starting material supply for UCART clinical studies and commercial products.

March

28 People Used

See More ››

Home Cellectis

Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq. Published on: March 29, 2021, 14:48 E.S.T. Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results. Published on: March 04, 2021, 14:59 E.S.T. Cellectis to Hold Fourth Quarter 2020 Earnings Call on Friday, March 5, 2021 at 8:00AM EST

View Contact ››

Location

41 People Used

See More ››

Cellectis Company Contact Information Email, Phone

Get Cellectis company's verified contact number +1*****625, web address, revenue, total contacts 88, industry Healthcare, Pharmaceuticals, & Biotech and location at Adapt.io

View Contact ››

Location

46 People Used

See More ››

Legal Notice Cellectis

View Contact ››

Phone

54 People Used

See More ››

Cellectis

Phone Number +1 (347) 752-4044 Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers.

View Contact ››

Purchase

49 People Used

See More ››

FAQs Cellectis

As of April 30, 2021, the number of shares constituting Cellectis’ capital is 45,461,310. As of the same date, the total number of voting rights is 51,526,159. How can I purchase Cellectis shares? To purchase Cellectis shares, you must have an account with a financial intermediary (bank, brokerage firm, online broker, etc.) and place your

View Contact ››

(Optional)

55 People Used

See More ››

Application Cellectis

Phone Number * Highest Degree Cover Letter (Optional) Message (Optional) Signup for our newsletter and stay up to date with whats happening at Cellectis. Send it Current vacancies. view vacancies 27 job opportunities. Legal notice Glossary Media library Contact Community guidelines.

View Contact ››

Cellectis

34 People Used

See More ››

Cellectis Company Profile

Cellectis has 253 employees across 4 locations and $33.72 M in annual revenue in FY 2017. See insights on Cellectis including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

View Contact ››

Email

54 People Used

See More ››

Contact Cellecta Cellecta, Inc

Email Addresses General information: [email protected]: [email protected]: [email protected] Support: [email protected] Inquiries: [email protected] If you wish to receive the latest news and product updates by email, please register or simply enter your email address to sign

View Contact ››

Cellebrite

48 People Used

See More ››

Contact

Cellebrite Pathfinder Find the path to insight through the mountains of data Cellebrite Frontliner Collecting with confidence on the frontline Cellebrite Reader Amplify findings and share information across departments Cellebrite Seeker Analyze and report all video evidence Cellebrite Inspector Quickly analyze computer and mobile devices to shed light on user actions Cellebrite Crypto Tracer

View Contact ››

Served

61 People Used

See More ››

Corporate Governance Cellectis

Governance. André Choulika, Ph.D., is one of the founders of Cellectis and served as Chief Executive Officer since the company's inception in 1999. He served as Chairman of the Board of Directors from 2011 to November 2020 and President of Calyxt from August 2010 to July 2020.

View Contact ››

Cellectis

67 People Used

See More ››

General Meetings Cellectis

Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer. Total number of voting rights: 51,531,739 *As of May 31, 2021. Legal notice Glossary Media library Contact Community guidelines.

View Contact ››

Please leave your comments here:

Popular Brands

Cnooc
Cae
Cerner
Crh
Csi
Copel
Cibc